Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)

v3.26.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance, Shares at Dec. 31, 2024   27,218,490      
Beginning balance at Dec. 31, 2024 $ (11,687) $ 3 $ 536,725 $ (9,770) $ (538,645)
Release of Restricted Stock Units and Performance Stock Units, Share   339,059      
Exercise of stock options, Shares   73,140      
Exercise of stock options 640   640    
Stock compensation expense 4,905   4,905    
Issuance of common stock under the Securities Purchase Agreements, net, Shares   4,843,750      
Issuance of common stock under the Securities Purchase Agreements, net, Value 36,047   36,047    
Net Income (Loss) (23,515)       (23,515)
Foreign currency translation adjustments, net of tax (2,675)     (2,675)  
Ending balance, shares at Mar. 31, 2025   32,474,439      
Ending balance at Mar. 31, 2025 3,715 $ 3 578,317 (12,445) (562,160)
Beginning balance, Shares at Dec. 31, 2025   34,615,132      
Beginning balance at Dec. 31, 2025 112,928 $ 3 605,700 (5,435) (487,340)
Beginning balance at Dec. 31, 2025 5,435        
Release of Restricted Stock Units and Performance Stock Units, Share   419,079      
Release of Restricted Stock Units and Performance Stock Units, Value $ 1 $ 1      
Exercise of stock options, Shares 2,879 2,879      
Exercise of stock options $ 21   21    
Stock compensation expense 3,963   3,963    
Net Income (Loss) (25,843)       (25,843)
Foreign currency translation adjustments, net of tax 166     166  
Net unrealized loss on investments (net of tax) (30)     (30)  
Ending balance, shares at Mar. 31, 2026   35,037,090      
Ending balance at Mar. 31, 2026 5,299        
Ending balance at Mar. 31, 2026 $ 91,206 $ 4 $ 609,684 $ (5,299) $ (513,183)